LEADER研究:2型糖尿病非严重低血糖频率与严重低血糖及主要心血管不良事件风险的相关性
该研究为LEADER试验的事后分析,探讨2型糖尿病患者非严重低血糖事件(NSHE)年发生率与严重低血糖、主要不良心血管事件(MACE)、心血管死亡及全因死亡的关系。结果显示,年NSHE≥12次与严重低血糖、MACE、心血管死亡和全因死亡风险升高相关,而年NSHE 2-11次仅与严重低血糖风险升高相关。
要点
- 年NSHE≥12次者严重低血糖风险显著升高(HR 5.01),MACE风险亦升高(HR 1.50)。
- 年NSHE 2-11次者仅与严重低血糖风险升高相关(HR 1.98),未发现心血管结局关联。
- 识别高频率低血糖患者有助于管理潜在心血管风险并减少NSHE。
核心结论
- 在2型糖尿病患者中,较高的NSHE年发生率与严重低血糖及不良心血管结局风险升高相关。
研究设计与样本
- LEADER试验(双盲、多中心、安慰剂对照)的事后分析,纳入所有LEADER参与者,采用含时变协变量的Cox回归。
主要发现
- 年NSHE 2-11次与严重低血糖风险升高相关(未调整HR 1.98,95%CI 1.43-2.75)。
- 年NSHE≥12次与严重低血糖风险升高相关(未调整HR 5.01,95%CI 2.84-8.84)。
- 年NSHE≥12次与MACE风险升高相关(HR 1.50,95%CI 1.01-2.23)。
- 年NSHE≥12次与心血管死亡风险升高相关(HR 2.08,95%CI 1.17-3.70)。
- 年NSHE≥12次与全因死亡风险升高相关(HR 1.80,95%CI 1.11-2.92)。
关键数值与推荐
- NSHE定义为自测血浆葡萄糖<3.1 mmol/L(56 mg/dL)。
- 严重低血糖定义为需要他人协助的事件。
- 参照组为年NSHE<2次者。
临床怎么用
- 临床应识别低血糖发生频率高的2型糖尿病患者,以管理其潜在升高的心血管事件风险,并采取措施减少NSHE。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Hypoglycaemia is a common side effect of insulin and some other antihyperglycaemic agents used to treat diabetes. Severe hypoglycaemia has been associated with adverse cardiovascular events in trials of intensive glycaemic control in type 2 diabetes. The relationship between non-severe hypoglycaemic episodes (NSHEs) and severe hypoglycaemia in type 2 diabetes has been documented. However, an association between more frequent NSHEs and cardiovascular events has not been verified. This post hoc analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial aimed to confirm whether there is an association between NSHEs and severe hypoglycaemic episodes in individuals with type 2 diabetes. In addition, the possible association between NSHEs and major adverse cardiac events (MACE), cardiovascular death and all-cause mortality was investigated. METHODS: LEADER was a double-blind, multicentre, placebo-controlled trial that found that liraglutide significantly reduced the risk of MACE compared with the placebo. In this post hoc analysis, we explored, in all LEADER participants, whether the annual rate of NSHEs (defined as self-measured plasma glucose <3.1 mmol/l [56 mg/dl]) was associated with time to first severe hypoglycaemic episode (defined as an episode requiring the assistance of another person), time to first MACE, time to cardiovascular death and time to all-cause mortality. Participants with <2 NSHEs per year were used as reference for HR estimates. Cox regression with a time-varying covariate was used. RESULTS: We demonstrate that there is an association between NSHEs (2-11 NSHEs per year and ≥12 NSHEs per year) and severe hypoglycaemic episodes (unadjusted HRs 1.98 [95% CI 1.43, 2.75] and 5.01 [95% CI 2.84, 8.84], respectively), which was consistent when baseline characteristics were accounted for. Additionally, while no association was found between participants with 2-11 NSHEs per year and adverse cardiovascular outcomes, higher rates of NSHEs (≥12 episodes per year) were associated with higher risk of MACE (HR 1.50 [95% CI 1.01, 2.23]), cardiovascular death (HR 2.08 [95% CI 1.17, 3.70]) and overall death (HR 1.80 [95% CI 1.11, 2.92]). CONCLUSIONS/INTERPRETATION: The analysis of data from the LEADER trial demonstrated that higher rates of NSHEs were associated with both a higher risk of severe hypoglycaemia and adverse cardiovascular outcomes in individuals with type 2 diabetes. Therefore, irrespective of the cause of this association, it is important that individuals with high rates of hypoglycaemia are identified so that the potentially increased risk of cardiovascular events can be managed and steps can be taken to reduce NSHEs. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01179048).
引用
- Heller SR, Geybels MS, Iqbal A, et al. A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia. 2021. PMID: 34704120. doi:10.1007/s00125-021-05556-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。